Status:
WITHDRAWN
Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency
Lead Sponsor:
Kaiser Permanente
Conditions:
Vitamin D Deficiency
Anemia
Eligibility:
All Genders
18+ years
Brief Summary
While vitamin D supplementation is safe and effective in repleting vitamin D levels in dialysis patients, the impact on anemia is unknown. The majority of hemodialysis patients require erythropoietin ...
Eligibility Criteria
Inclusion
- All hemodialysis patients at the Kaiser Permanente Los Angeles Medical Center with vitamin D deficiency \[defined by 25-hydroxyvitamin D level less than 30 ng/ml\]
Exclusion
- Non-renal causes of anemia (myelodysplastic syndrome, multiple myeloma, pure red cell aplasia, thallassemia, and sickle cell anemia)
- Active cancer
- AIDS
- refused erythropoeitin, intravenous iron or vitamin D analogs in the past
- no erythropoeitin requirement for greater than 6 weeks
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00915317
Start Date
October 1 2008
End Date
March 1 2009
Last Update
March 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Southern California
Los Angeles, California, United States, 90027